6
Dec
2017
“You Went to SITC and All You Got Was This TR Post? (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Nov
2017
Codiak, Aspiring to Make Exosome Drugs for Cancer, Nabs $76M to March Into Clinic
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Nov
2017
Understanding Polio, Baseball and Cancer: Sometimes the “When” is as Vital as the “What”
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Oct
2017
VIDEO: Climbing Mount Everest to Support Cancer Research at Fred Hutch
Hi, I’m Luke Timmerman, a biotech journalist. I’m carrying my 80-pound training backpack, up and down the hills of Seattle, for a reason. I’m training to climb Mt. Everest, the highest mountain in the world, in 2018. Why do this? Of course, I love the mountains. But mostly, I’m doing it to support the top-notch research at the Fred Hutchinson...Read More
2
Oct
2017
KSQ Scores $76M, Lures Meeker to CRISPR Dream of ‘High Confidence Drug Development’
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Sep
2017
Replimune, Led by BioVex Vets, Snags $55M for New Oncolytic Viruses for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Sep
2017
Gritstone Grabs $93M, Doubling Down on Personalized Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Aug
2017
Getting to Precision Medicine – It’s Complicated
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jul
2017
A One-Bug Drug For the Immune System? Evelo Gets $50M to Test Concept
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jun
2017
Repare Secures $68M Series A to Discover ‘Synthetic Lethal’ Cancer Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jun
2017
ASCO Takeaways A-Z (Part 2)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2017
ASCO Takeaways From A-Z (Part 1)
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jun
2017
ASCO Notebook: Observations on Cancer R&D from Foundation Medicine, Halozyme, Blueprint, Nektar
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Apr
2017
AACR Reflections: Genomics Adapts to I-O World, Scientists Stand Up, and Re-Thinking How to Fight Early-Stage Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
30
Mar
2017
Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Mar
2017
Dunsire Joins Xtuit to Fight Microenvironment; Spero Gets $51.7M for Antibiotics
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Feb
2017
Now More Than Ever: The Need for Personalized Medicine in Immuno-Oncology
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jan
2017
Neon Therapeutics Gets $70M to Push Neoantigen Cancer Vaccines
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Sep
2016
Google Translate Star Leaves Venter’s Human Longevity to Join Illumina’s Grail
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jun
2016
The VP is Asking for Advice on Cancer. Share Yours Before I Go To Washington
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.